TGFB1 and neoplasm: Moreover, the innovative application of a bifunctional antibody, Y-trap, capable of targeting both TGFβ and CTLA-4, has also proven effective in mitigating immune tolerance and augmenting tumour-infiltrating lymphocytes [139].